HotCharts

Bullish Charts - Plasma Play, FDA Approved Plasma Facilities

Long
NASDAQ:ADMA   ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

BREAKING NEWS TODAY - 07/30/2020

ADMA Biologics shares are trading higher following a report suggesting the company is near receiving emergency use authorization of Convalescent Plasma in COVID-19 patients.

www.benzinga.com/wii...ny-is-near-receiving

On July 6, 20, ADMA opened a new plasma facility and is awaiting emergency authorization for a second location.

finance.yahoo.com/ne...-adma-110010457.html

With the FDA asking for everyone to donate plasma, this stock could rip!

Plasma stocks ripped today and continue to rip.

This company already is up and running one plasma facility.

Game On!

Long

DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.